DARe is currently investigating three fundamental processes associated with aging and age-related diseases that have potential to deliver novel therapeutic approaches. These processes are intricately ...

To advance the work we do for and with communities, we look to connect with experts and listen to diverse voices. From patients and care partners to health care teams, hearing from all individuals ...

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C) 1 4 out of 5 atherosclerotic ...

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been ...

Rapid approvals in eight African countries now expected under a special global health scheme run by Swiss agency for therapeutic products (Swissmedic) Novartis plans to introduce infant-friendly ...

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile 1 Sustained clinical benefit from Kymriah ...

FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)1 ...

The information in the presentation on this page was factually accurate on the date of publication. This presentation remains on the Novartis website for historical purposes only. Novartis assumes no ...

Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading ...

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal disease Lead asset for ADPKD ...

Novartis Chief Digital Officer, Bertrand Bodson and Microsoft Healthcare Corporate Vice President, Peter Lee also discussed the potential of data science and AI during a recent visit to Novartis ...